{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:36:21Z","timestamp":1793756181635,"version":"4.6.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bexagliflozin exerts definite efficacy in the treatment of type 2 diabetes mellitus (T2DM). However, whether this novel sodium-glucose cotransporter 2 (SGLT2) inhibitor is superior to other SGLT2 inhibitors remains to be elucidated. We therefore performed this network meta-analysis (NMA) to compare bexagliflozin with other SGLT2 inhibitors and establish an efficacy hierarchy in T2DM management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Web of Science and the ClinicalTrials.gov registry for eligible randomized controlled trials (RCTs) published up to January 2026. Statistical analysis was conducted using Stata 14.0. Risk of bias was assessed by the Cochrane tool, evidence certainty was evaluated using the Confidence in Network Meta-Analysis (CINeMA) approach, and intervention ranking was performed using surface under the cumulative ranking curve (SUCRA) values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This NMA included 48 studies with 26,838 patients. Bexagliflozin significantly reduced HbA1c, fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared with placebo. For HbA1c reduction, canagliflozin (300 mg, 100 mg) and empagliflozin 25 mg were more effective than bexagliflozin, while bexagliflozin was comparable to other SGLT2 inhibitors. For FPG reduction, canagliflozin 300 mg and empagliflozin 25 mg showed slightly greater effects than bexagliflozin, with no significant differences between bexagliflozin and other comparators. Bexagliflozin was superior to dapagliflozin 5 mg but slightly inferior to canagliflozin 300 mg for weight loss, while showing comparable efficacy to other SGLT2 inhibitors. It achieved similar SBP and DBP reduction to other SGLT2 inhibitors, with a significantly greater DBP-lowering effect than empagliflozin 10 mg. Bexagliflozin had a lower incidence of urinary tract infection than dapagliflozin (5 mg, 10 mg), with comparable safety to other agents and placebo. Canagliflozin 300 mg showed the best efficacy for HbA1c, FPG and weight control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bexagliflozin demonstrates comparable efficacy to most SGLT2 inhibitors in T2DM patients, with a relatively prominent benefit in body weight reduction and a similar safety profile. Canagliflozin 300 mg provides more effective glycemic and weight control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1843370","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:48:13Z","timestamp":1778647693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Shan","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Deyang People\u2019s Hospital","place":["Deyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yaan People\u2019s Hospital","place":["Yaan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Good Clinical Practice, Yaan People\u2019s Hospital","place":["Yaan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.29309\/tpmj\/2016.23.09.1703","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04027-5","article-title":"The global macroeconomic burden of diabetes mellitus","volume":"32","author":"Chen","year":"2026","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s2213-8587(14)70148-2","article-title":"Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review","volume":"3","author":"Geijselaers","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0493","article-title":"Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: a diffusion tensor imaging study","volume":"36","author":"Reijmer","year":"2013","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2007.s15","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B7","volume-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.7357","article-title":"Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors","volume":"185","author":"Shin","year":"2025","journal-title":"JAMA Intern Med"},{"key":"B9","volume":"43","year":"2023","journal-title":"Int J Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2269854","article-title":"Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Dholariya","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B12","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2011"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B15","article-title":"Chapter 11: Undertaking network meta-analyses","volume-title":"Cochrane handbook for systematic reviews of interventions version 61","author":"Anna","year":"2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","article-title":"Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data","volume":"68","author":"Rhodes","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3167\/ijsq.2018.080205","article-title":"Evidence Based Social Science in China Paper 3: The quality of social science RCTs published from 2000-2020","volume":"141","author":"Li","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13833","article-title":"A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes","volume":"21","author":"Halvorsen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13928","article-title":"A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes","volume":"22","author":"Halvorsen","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.03.417","article-title":"Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a\/3b CKD","volume":"74","author":"Allegretti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B23","article-title":"Safety and efficacy of bexagliflozin as monotherapy in patients with type 2 diabetes","volume-title":"ClinicalTrials.Gov identifier: NCT02715258","author":"Lock","year":"2016"},{"key":"B24","article-title":"Bexagliflozin efficacy and safety trial (BEST)","volume-title":"ClinicalTrials. gov identifier: NCT02558296","author":"Lock","year":"2015"},{"key":"B25","article-title":"Safety and efficacy of bexagliflozin compared to placebo as add-on therapy to metformin in type 2 diabetes subjects","volume-title":"ClinicalTrials.Gov identifier: NCT03259789","author":"Lock","year":"2017"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12047","article-title":"Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Kaku","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12325","article-title":"Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise","volume":"16","author":"Kaku","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3109\/9780849379581-10","article-title":"Durability and tolerability of dapagliflozin over 52\u2009weeks as add-on to metformin and sulphonylurea in type 2 diabetes","volume":"17","author":"Matthaei","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.12387","article-title":"Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial","volume":"17","author":"Schumm-Draeger","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"J Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12634","article-title":"Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial","volume":"10","author":"Yang","year":"2018","journal-title":"J Diabetes"},{"key":"B43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","article-title":"Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Inagaki","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.935764","article-title":"Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study","volume":"15","author":"Inagaki","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/dom.12385","article-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea","volume":"17","author":"Ji","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12149","article-title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study","volume":"15","author":"Inagaki","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13909","article-title":"Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Sone","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Adv Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12081","article-title":"A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes","volume":"15","author":"Ferrannini","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.12469","article-title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial","volume":"17","author":"Ross","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13681","article-title":"Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia","volume":"21","author":"Ji","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study","volume":"20","author":"Dagogo-Jack","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12460","article-title":"Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000005473","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"95","author":"Xiong","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000016575","article-title":"Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"98","author":"Feng","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000012843","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials","volume":"97","author":"Zhang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5553327","article-title":"Efficacy and safety of ertugliflozin compared to placebo in patients with type 2 diabetes: an updated systematic review and meta-analysis","volume":"2024","author":"Kamrul-Hasan","year":"2024","journal-title":"J Diabetes Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15051","article-title":"Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"25","author":"Pasqualotto","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"6","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1843370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:48:39Z","timestamp":1778647719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1843370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":77,"alternative-id":["10.3389\/fendo.2026.1843370"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1843370","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1843370"}}